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Overactivation of the alternative pathway of the complement system is associated with 
the renal diseases atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy 
(C3G). C3 nephritic factors (C3NeF) play an important role in C3G pathogenesis by 
stabilizing the key enzymatic complex of complement, the C3 convertase. However, the 
reliability of assays detecting these autoantibodies is limited. Therefore, in this study, we 
validated and optimized a prototype hemolytic method for robust detection and charac-
terization of factors causing convertase overactivity in large patient cohorts. The assay 
assesses convertase activity directly in the physiological milieu of serum and therefore 
is not restricted to detection of stabilizing autoantibodies such as C3NeF but may also 
reveal genetic variants resulting in prolonged convertase activity. We first defined clear 
cutoff values based on convertase activity in healthy controls. Next, we evaluated 27 C3G 
patient samples and found 16 positive for prolonged convertase activity, indicating the 
presence of factors influencing convertase stability. In three patients, the overactive con-
vertase profile was persistent over disease course while in another patient the increased 
stability normalized in remission. In all these four patients, the convertase-stabilizing 
activity resided in the purified immunoglobulin (Ig) fraction, demonstrating the autoan-
tibody nature. By contrast, the Igs of a familial aHUS patient carrying the complement 
factor B mutation p.Lys323Glu did not reveal convertase stabilization. However, in serum 
prolonged convertase activity was observed and segregated with the mutation in both 
affected and unaffected family members. In conclusion, we present a robust and reliable 
Abbreviations: aHUS, atypical hemolytic uremic syndrome; AP, alternative pathway; C3G, C3 glomerulopathy; C3GN, C3 
glomerulonephritis; C3NeF, C3 nephritic factor; CR1, complement receptor 1; DAF, decay-accelerating factor; DDD, dense 
deposit disease; EDTA, ethylenediaminetetraacetic acid; EDTA–GVB, EDTA–gelatin veronal buffer; FB, complement factor B; 
FD, complement factor D; FH, complement factor H; FHaAb, FH autoantibodies; FI, complement factor I; Ig, immunoglobulin; 
MAC, membrane attack complex; MCP, membrane cofactor protein; Mg–EGTA, magnesium–ethylene glycol tetraacetic acid; 
NHS, pooled normal human serum; NHP, pooled normal human plasma.
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method for the detection, characterization, and evaluation over time of factors prolong-
ing convertase activity (C3NeF or certain mutations) in patient cohorts. This assay may 
provide new insights in disease pathogenesis and may contribute to the development of 
more personalized treatment strategies.
Keywords: complement system, alternative pathway, convertase, c3 nephritic factor, c3 glomerulopathy, atypical 
hemolytic uremic syndrome, complement factor B mutation
amplification loop of the AP can also be induced by C3b mol-
ecules generated by C3 convertases from the other two activation 
pathways. In this way, the AP can account for over 80% of total 
complement activity. Thus, besides being a surveillance system, 
the AP acts as an important amplifier of initiated complement 
responses (1, 4, 5).
The powerful action of the AP requires sophisticated regula-
tion to prevent damage by excessive activation or self-attack. 
Therefore, human cells express membrane-bound complement 
inhibitors, including decay-accelerating factor (DAF), membrane 
cofactor protein (MCP), and complement receptor 1 (CR1). 
Together with the soluble regulatory proteins complement factor 
H (FH) and complement factor I (FI), which can act in fluid phase 
or can be recruited to surfaces, these complement regulators 
prevent the formation of potent C3 convertases on healthy host 
surfaces and keep AP activity in control. The inhibitors of the C3 
convertase can act via two ways. The first is by accelerating the 
convertase decay and is fulfilled by DAF, CR1, and FH. These reg-
ulators can also compete with FB for binding to C3b and thereby 
inhibit new convertase formation. The second is by preventing 
convertase formation via acting as cofactors for FI-mediated 
inactivation of C3b. This action is supported by MCP, CR1, and 
FH (7–9). However, genetic aberrations in complement genes 
and/or autoantibodies against complement components may, in 
combination with triggering events, disturb this sophisticated 
regulation, causing overactivation of the system. A dysregulated 
AP has been particularly associated with the renal diseases the 
atypical hemolytic uremic syndrome (aHUS) and the disease 
entity C3 glomerulopathy (C3G) (10–15).
C3 glomerulopathy is a recently defined umbrella classification 
for severe renal diseases that are characterized by C3 accumula-
tion in the glomeruli without or with sparse immunoglobulin 
(Ig) deposition. The main two diseases encompassed by C3G 
are dense deposit disease (DDD) and C3 glomerulonephritis 
(C3GN) (16). Up to 50% of patients progress to end-stage renal 
disease within 10  years after first presentation (17). The most 
important pathogenic factors in C3G are autoantibodies against 
the C3 convertase of the AP named C3 nephritic factors (C3NeF), 
although pathogenic variants in complement genes have also 
been reported (14, 15). By binding to neoepitopes of the formed 
C3bBb(P), C3NeF stabilizes the otherwise labile convertase and 
thereby prolongs its half-life (18). C3NeF has been detected 
in approximately 80–90% of DDD patients (15, 19, 20) and in 
40–50% of patients with C3GN (15, 21).
Atypical HUS is a form of thrombotic microangiopathy and is 
not associated with C3NeF, but pathogenic mutations in comple-
ment genes or autoantibodies against FH are the most common 
cause of improper complement regulation (22–25). Blocking 
inTrODUcTiOn
The complement system, a cornerstone of innate immunity, 
provides the body with protection against invading pathogens 
and dangerous host cells (1, 2). The system can be activated via 
three pathways—the classical, lectin and alternative pathway 
(AP)—depending on the initial trigger that is encountered. All 
pathways converge at the central event of complement activation: 
the cleavage of C3 by C3 convertases. This enzymatic reaction 
supports further activation of the complement cascade with the 
release of various anaphylatoxins and opsonins, and eventually 
the formation of the membrane attack complex (MAC). These 
events all contribute to inflammation, phagocytosis and the dam-
age of susceptible targets (1–3).
In contrast to the classical and lectin pathway, which are 
only activated upon pattern recognition, the AP is continuously 
mildly activated and therefore specifically serves as a surveillance 
mechanism. C3 is subjected to spontaneous hydrolysis of its 
internal thioester bond at a very low rate, and this generates the 
active C3(H2O) molecule. Hydrolyzed C3 can bind to comple-
ment factor B (FB), which is subsequently cleaved by complement 
factor D (FD) to form an initial, fluid phase AP C3 convertase, 
C3(H2O) Bb, that is capable of converting native C3 into the 
active C3a (anaphylatoxin) and C3b (opsonin) fragments. This 
mechanism providing a persistent low level of active C3 in the 
blood is known as “tick-over” and allows constant responsiveness 
to potential danger. Besides the tick-over mechanism, the AP 
may also be initiated by C3 convertases of the classical and lectin 
pathway that generate active C3b (1, 4, 5). Furthermore, C3 may 
be cleaved into C3b by certain non-specific proteases, especially 
at sites of inflammation, coagulation, and infection (6).
Activated C3b molecules expose a reactive thioester moiety 
via which they can subsequently bind to hydroxyl or amino 
groups on target surfaces in close proximity to the activation site. 
This C3b binding, and thus initiation of AP activity, is preferen-
tially triggered by certain carbohydrate structures on microbes 
and other foreign surfaces, e.g., LPS and zymosan. By interacting 
with FB and FD, target-bound C3b can subsequently form new 
surface-bound convertases (C3bBb) that can be further stabilized 
by properdin (C3bBbP). Properdin has also been proposed 
to act as a pattern recognition molecule able to initiate the AP 
on certain targets by recruiting C3b and FB. Once formed, AP 
C3 convertases can massively amplify the immune response by 
converting more C3 molecules into C3b, which in turn support 
new convertase formation. Incorporation of C3b into existing 
C3 convertases generates C5 convertases (C3bBbC3b), which 
cleave C5 into the potent anaphylatoxin C5a and the fragment 
C5b that initiates the assembly of the MAC (C5b-9) complex. The 
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C5 and terminal pathway activation with the C5-directed anti-
body eculizumab is a very effective treatment for this disease. 
Eculizumab became the first approved complement-inhibiting 
drug for aHUS in 2012 (26, 27). By contrast, trials of eculizumab 
treatment in C3G patients have shown contradicting outcomes so 
far. Thus, the value of eculizumab as a therapy for C3G requires 
further investigation (17, 28, 29).
Detection of C3NeF is not only helpful in diagnosis of C3G 
but also in choice of therapy for the patient, especially in the light 
of upcoming complement-inhibiting strategies. Nevertheless, 
a robust and reproducible method for C3NeF detection is still 
lacking. A recent European quality assessment round reported 
a success rate of only 50% among the participating laboratories 
(30). This also hampers our understanding of the exact role of 
C3NeF in C3G pathogenesis. C3NeF are functionally heterogene-
ous (31) and conflicting associations have been found between 
its presence and the patient’s disease state and progression (20, 
32–34). Some reports even describe C3NeF in healthy individuals 
(35, 36).
Recently, we described a new hemolytic method for measure-
ment of convertase activity in the physiological milieu of whole 
serum. This assay allows the robust detection of factors prolong-
ing convertase stability in a direct way, such as C3NeF, and/or 
in an indirect way by impairing the regulation of the convertase 
(37). For convenience, we will use the term convertase-stabilizing 
factors for both these types of factors that are either directly or 
indirectly prolonging the convertase half-life. The assay uses 
C5-blocking agents [eculizumab or the tick protein Ornithodoros 
moubata complement inhibitor (OmCI) (37, 38)] to strictly 
separate the complement cascade into two steps: the formation 
of C3/C5 convertases by test sera in a first step and the forma-
tion of lytic MAC complexes in a standardized second step for 
readout. Dynamics of convertase assembly and decay in the first 
step are then monitored in time. In this work, we further modified 
this convertase activity assay to screen for convertase-stabilizing 
factors in patient cohorts by defining clear cutoff criteria based 
on healthy controls. In addition, we showed expanded analysis 
of clinical samples with different types of convertase-stabilizing 
factors and their presence over disease course.
MaTerials anD MeThODs
sample collection
Whole blood was obtained from patients and healthy controls 
and processed within 1 h after sampling. For serum, blood was 
allowed to clot at room temperature for 30–45 min followed by 
centrifugation (10 min, 2,500 g, 4°C). To obtain plasma, blood 
was drawn into tubes with the anticoagulant ethylenediamine-
tetraacetic acid (EDTA) that were immediately placed on ice 
and subsequently centrifuged according to the same procedure. 
Afterward, the serum and EDTA plasma fractions were collected, 
aliquoted, and stored at −80°C until use. For the healthy controls, 
following exclusion criteria were applicable: fever, bacterial/
viral infection in previous 2 weeks, chronic illness, inherited or 
acquired immune disorders, and immunosuppressive medica-
tion. In addition, pooled normal human serum (NHS) and 
pooled normal human plasma (NHP) were made by pooling 
15 and 12 individual control samples, respectively. This study 
was carried out in accordance with the recommendations of the 
appropriate version of the Declaration of Helsinki. All subjects 
gave written informed consent, and the protocol was approved by 
the ethical committee of the Radboud University Medical Center 
(FH 06979).
erythrocyte Working suspensions
Rabbit erythrocytes (RbE) in Alsever’s solution were obtained 
from Envigo (Venray, the Netherlands). The working suspensions 
of RbE were prepared by washing them with magnesium–ethyl-
ene glycol tetraacetic acid (Mg–EGTA) buffer (2.03 mM veronal 
buffer, pH 7.4, 10  mM EGTA, 7  mM MgCl2, 0.083% gelatin, 
115 mM d-glucose, and 60 mM NaCl) until there was no visible 
hemoglobin left in the supernatant. To standardize the number of 
erythrocytes in each experiment, these working suspensions were 
calibrated so the absorbance measured at 405 nm of 10× diluted 
erythrocytes in water was between 0.8 and 1.2.
ig Purification
The Ig fractions from NHP and from the EDTA plasma of 
patients P24, P25, P26, and P27 (Table 1) were isolated by affin-
ity purification using NAb™ protein A/G 5  mL spin columns 
(Thermo Fisher Scientific, Waltham, MA, USA) according to 
the manufacturer’s protocol. In short, 0.85–1.0  mL of EDTA 
plasma was diluted with binding buffer (0.1  M phosphate, 
0.15 M sodium chloride, and pH 7.2) to 10 mL and loaded on the 
columns. Unbound fractions were washed with binding buffer, 
and thereafter bound Igs were eluted using 0.1 M glycine, pH 2.5 
followed by immediate neutralization with 1/10 volume 1 M Tris, 
pH 8.5. Subsequently, Ig fractions were dialyzed against phos-
phate buffered saline using SnakeSkin® dialysis tubes (Thermo 
Fisher Scientific, Waltham, MA, USA) with a 10 kD molecular 
weight cutoff and concentrated to the initial plasma sample 
volume using Amicon® Ultra-15 centrifugal filter devices (Merck 
Millipore, Billerica, MA, USA) with similar cutoff. Total protein 
concentrations in these samples were measured using NanoDrop 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA) and varied between 4.73 and 12.48  mg/mL, which are 
within the normal range for Igs.
convertase activity assay
Detection of AP convertase-stabilizing factors in human serum 
was achieved using a two-step hemolytic assay as previously 
described (37) and as further specified in Figure 1. Briefly, per 
experimental time point 10  µL of prepared RbE were mixed 
with 20  µL Mg–EGTA containing 150  nM of the C5 inhibitor 
eculizumab (Alexion Pharmaceuticals, Cheshire, CT, USA), after 
which at different time points an additional 20 µL Mg–EGTA con-
taining test serum or Ig fractions mixed 1:1 with NHS was added 
for convertase assembly (5, 10, 15, 20, 30, 40, 50, or 60 min). Final 
concentrations of serum were optimized per batch of erythrocytes 
and were generally 3.75 or 5%. Subsequently, cells were washed 
with 150 µL 40 mM EDTA–gelatin veronal buffer (EDTA–GVB, 
4.41 mM veronal buffer, 0.1% gelatin, 130 mM NaCl, pH 7.4) and 
collected by centrifugation (2 min, 1,000 g, room temperature). 
TaBle 1 | Clinical and genetic data.
Patient/subject gender 
(M/F)
age at time of 
study (years)
Diagnosis genetic aberrationsb convertase-
stabilizing factors 
present (Y/n)
c3 levelsg  
(mg/l; 700–1500)
(a) c3g cohort
P1 M 63 DDD N NA
P2 M 10 C3GN N NA
P3 M 66 C3GN N 588
P4 M 52 DDD C3 c.26T>C (p.Leu9Pro)c located in signal sequence N NA
P5 M 43 C3GN N Normal
P6 F 42 C3GN N Normal
P7 M 37 C3GN N 941
P8 F 33 C3Ga N NA
P9 M 6 DDD N 644 
P10 M 9 C3Ga N 660
P11 M 11 C3GN N 530 
P12 F 44 C3GN Y 102
P13 M 7 DDD CFI c.1217G>A (p.Arg406His)d (39) Y Decreased
P14 F 19 C3Ga CFH c.2850G>T (p.Gln950His)e (15), f(40) Y NA
P15 M 27 C3GN C3 c.962G>A (p.Gly321Glu)c Y NA
P16 F 6 C3GN CFH full length deletionc Y 500
P17 F 7 C3Ga Y NA
P18 M 10 C3GN Y 220
P19 M 7 DDD Y 210
P20 F 9 DDD Y 100
P21 F 7 DDD Y 510
P22 M 5 DDD Y 110
P23 M 15 C3GN Y NA
P24 F 8 C3GN CFHR5 c.542G>C (p.Arg181Thr)c Y 110
P25 M 9 DDD Y 82
P26 F 5 C3GN Y 830
P27 M 15 C3GN Y 70
(b) Family with complement factor B mutation and ahUs
II. 5 M 41 – N
II. 6 F 40 – CFB c.967A>G (p.Lys323Glu)f (41, 42) Y
III. 1 F 22 – N
III. 2 M 18 – N
III. 4 F 14 aHUS CFB c.967A>G (p.Lys323Glu)f (41, 42) Y
III. 5 F 7 – N
III. 6 F 4 aHUS CFB c.967A>G (p.Lys323Glu)f (41, 42) Y 260
aNo distinction possible into C3GN or DDD, since no electron microscopy was performed or no data available.
bAll genetic variants found were heterozygous.
cTo the best of our knowledge, not previously reported in context of C3G.
dPreviously reported in a DDD patient.
ePreviously reported in C3GN patients.
fPreviously reported in aHUS patients.
gC3 levels were measured by nephelometry with the normal range indicated between brackets. Data given are those available as closest to the time of convertase activity 
assessment. For samples obtained from peripheral centers and from which C3 data were accessible, results are presented as “normal” or “decreased” since normal ranges vary 
between centers.
aHUS, atypical hemolytic uremic syndrome; C3G, C3 glomerulopathy; C3GN, C3 glomerulonephritis; DDD, dense deposit disease; NA, not available.
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Thereafter, cells were incubated for 60 min with 50 µL of 2.5% 
guinea pig serum (Envigo, Venray, the Netherlands) in EDTA–
GVB and another 50 µL of Mg–EGTA buffer to develop MAC 
and subsequent hemolysis. All incubation steps were performed 
at 37°C, with 600 rpm agitation in a VWR® Incubating Microplate 
Shaker with 3 mm orbit (VWR International, Radnor, PA, USA) 
in V-shaped 96-well plates (Greiner Bio-One, Kremsmünster, 
Austria). Finally, supernatant was collected by centrifugation 
and transferred to flat-bottom 96-well plates (Greiner Bio-One, 
Kremsmünster, Austria). Hemolysis was quantified as percentage 
of full lysis by an equal amount of erythrocytes in water: (A405 test 
sample − A405 blank)/(A405 full lysis − A405 blank) × 100.
statistical analysis
Where indicated, data were analyzed using two-way analysis of 
variance with Bonferroni’s post test using GraphPad Prism 5.03 
for Windows (GraphPad Software, San Diego, CA, USA).
resUlTs
study cohort
A group of 27 patients diagnosed with C3G and referred to the 
Radboud University Medical Center were included in the study. 
Diagnosis was suspected based on presence of clinical features such 
FigUre 1 | Principles of the convertase activity assay for detecting convertase-stabilizing factors in serum. In step 1, rabbit erythrocytes (RbE) are incubated in an 
alternative pathway (AP)-permissive buffer with test serum mixed 1:1 with pooled normal human serum (NHS) to compensate for possible C3 depletion in the test 
sample. The C5 inhibitor eculizumab is added to halt complement activation at the level of the C3/C5 convertases. Convertase assembly and decay are followed 
over time using different incubation times (5–60 min). Convertase-stabilizing factors present in the sample, e.g., C3 nephritic factor (C3NeF), may interfere at this 
point with convertase decay. Before proceeding to step 2, erythrocytes are washed to remove remaining complement factors and C5 inhibitor. Then, convertase-
bearing erythrocytes are incubated for 60 min with guinea pig serum as a source of membrane attack complex (MAC) components. The presence of 
ethylenediaminetetraacetic acid (EDTA) disables de novo formation of convertases from guinea pig serum and assures that only preformed convertases of the first 
step may initiate MAC formation and subsequent hemolysis. The released hemoglobin is quantified by spectrophotometric measurement and reflects the activity of 
the preformed convertases in step 1 per experimental time point. These data are used to generate convertase activity profiles over time. *If desired, immunoglobulin 
fractions may be added to NHS to dissect the nature of the stabilizing factor (see Materials and Methods).
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as hypertension, proteinuria, and nephrotic/nephritic syndrome, 
possibly combined with low serum C3. Diagnosis was confirmed 
after pathological judgment of renal biopsy following the recom-
mendations defined in the consensus report of the first C3G Meeting 
(16). Subdivision of C3G into C3GN and DDD was solely based on 
electron microscopy appearance. In total, 9 patients were diagnosed 
with DDD, 14 with C3GN, and in 4 patients no distinction between 
the C3G subforms could be made since data required for subdivi-
sion were not available. In this C3G cohort (age range: 5–66 years; 17 
children, 10 adults), no FH autoantibodies (FHaAb) were detected, 
and 6 patients carried mutations in complement (regulating) genes 
(Table 1a). Besides samples from C3G patients, sera from a female 
patient with familial aHUS and six of her affected and non-affected 
family members were available for analysis. In total, three of these 
family members were carrier of the heterozygous FB p.Lys323Glu 
mutation and two of them were also affected with aHUS (Table 1b).
convertase activity in healthy Donors
To define normal convertase activity, we tested the sera of 15 
healthy controls (Figure 2). Due to low serum C3 levels in vivo, 
FigUre 2 | Convertase activity in serum samples of healthy controls. 
Samples collected from 15 healthy controls were mixed 1:1 with pooled 
normal human serum (NHS) to an end concentration of 3.75%. Heat-
inactivated NHS (ΔNHS) and an NHS sample from which guinea pig serum 
was omitted during the second part of the assay (no step 2) served as 
negative controls for the first and second steps, respectively. Means are given 
of ≥2 independent experiments for each control. Error bars were omitted for 
better visibility of the graph. Hemolysis levels are presented as percentage of 
full lysis of erythrocytes in water.
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many C3G samples show low hemolytic activity. To compensate 
for this possible complement consumption, all samples in this 
study, including those from controls, were diluted 1:1 with NHS. 
We previously showed that this approach restored hemolytic 
activity while still allowing the detection of convertase-stabilizing 
factors in patient serum (37) (also see Figure S1 in Supplementary 
Material). The convertase activity profiles of healthy controls 
demonstrated a constant pattern, which was comparable to that of 
NHS. Convertase activity reached its maximum after 10–15 min 
of incubation, and at 30  min activity returned to background 
levels in all control samples.
The ratio between the highest achieved hemolysis (top) and the 
lysis at the point at which controls have returned to background 
levels, in this case at t = 30 min (t30), was 5.4 ± 2.7 (mean ± 2 SD) for 
healthy controls. Prolonged convertase activity, i.e., delayed decay, was 
defined as a top/t30 ratio below the mean − 2 SD of controls, here <2.7. 
Because samples with a low hemolytic activity overall are also likely to 
be positive for this criterion, only samples that have a total area under 
the curve equal to or higher than that of NHS are considered positive.
convertase activity in Patients
Next, we analyzed convertase activity in the cohort of 27 C3G 
patients. Samples were first screened at t30 in a single time point 
screening (Figure  3A). The 21 samples that at t30 showed lysis 
above that of NHS (18.7%) were selected for further analysis of 
convertase activity over time. All other samples were considered 
negative for the presence of convertase-stabilizing factors.
Of the 21 patients who were selected for analysis of the 
convertase activity profile, 16 showed a top/t30 ratio below 
2.7 (Figure  3B). These samples were considered positive for 
convertase-stabilizing factors. The other five samples, selected 
in the initial screening as possibly positive, did not meet these 
criteria and were therefore considered to have normal convertase 
activity profiles (Figure 3C).
convertase activity Over Disease course
Subsequently, we investigated whether convertase activity pro-
files could change over disease course. From four patients who 
showed increased convertase stability, P24–P27 (Table 1), serum 
samples were available derived over different periods of their 
disease, e.g., from active disease states and/or (partial) remission 
periods. The active disease state samples of P24 and the active dis-
ease and partial remission samples of P27 all displayed prolonged 
convertase activity (Figures 4A,B). Also P25 showed a persistent 
stabilized convertase profile in both active disease and in partial 
and complete remission (Figure 4C). By contrast, the prolonged 
convertase activity shown for P26 was only detected in the acute 
phase and normalized in remission (Figure 4D).
Prolonged convertase activity due to 
autoantibodies
For these four patients, we then investigated whether the 
convertase-stabilizing effect was due to autoantibodies such 
as C3NeF (Figure  5). To this end, the Ig fractions from these 
patients were purified using protein A/G affinity chromatogra-
phy. Samples were concentrated in phosphate buffered saline to 
the initial plasma sample volume. Addition of an equal volume 
of the purified Ig fractions to NHS revealed comparable stabiliz-
ing effects on the convertases as seen for these patient’s serum 
samples. This stabilization could not be observed when healthy 
control Igs were added to NHS. Thus, in these patients prolonged 
convertase activity could be attributed to autoantibody activity.
Prolonged convertase activity due to FB 
Mutation in ahUs Family
Previously, we described prolonged convertase activity in the 
serum of an aHUS patient carrying the p.Lys323Glu mutation in 
FB (37). In this study, we analyzed convertase activity in available 
serum samples of affected and unaffected family members of this 
patient (Figure  6A). Stabilized convertase profiles segregated 
with the FB mutation in both affected and non-affected family 
members (Figure 6B). When purified total Igs of the index patient 
were added to NHS, no stabilization of the C3 convertase could 
be observed (Figure 6C), unlike Ig fractions from C3G patients 
(Figure  5). This indicates that in these individuals, prolonged 
convertase activity could be attributed to the FB mutation rather 
than to autoantibody activity.
DiscUssiOn
Previously, we described proof-of-concept of a robust method 
to measure C3 convertase activity allowing detection of factors 
influencing convertase activity in whole serum. Here, we further 
standardized assay conditions for screening in patient cohorts 
and for critical evaluation of convertase-stabilizing factors in 
clinical samples.
We showed low variation among healthy controls in the 
assay (Figure 2) and based on this defined clear cutoff criteria 
for assessing the presence of convertase-stabilizing factors in 
patient samples. The samples were considered positive when they 
showed a top/t30 ratio lower than the mean −  2 SD of healthy 
FigUre 3 | Screening for convertase-stabilizing factors in patients with C3 glomerulopathy (C3G). (a) Convertase activity of 27 patients with C3G as measured in a 
single time point screening with 30 min of incubation time. Samples showing hemolysis above that of pooled normal human serum (NHS), represented by the dotted 
line, are indicated with colored symbols and were selected for further analysis of convertase activity over time. (B,c) Convertase activity profiles of the 21 patients 
selected from the t30 screening in panel (a). Samples positive for convertase-stabilizing factors (top/t30 ratio < 2.7) are given in panel (B); samples negative for the 
presence of convertase-stabilizing factors (top/t30 ratio > 2.7) in panel (c). Results given are from a single assay set representative for at least two performed on 
each sample. (a–c) Serum samples were all tested mixed 1:1 with NHS to a final concentration of 3.75%. Colors and symbols correspond to the same patients in 
all panels. Hemolysis levels are given as percentage of full lysis of erythrocytes in water.
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controls in their convertase activity profile. Cutoff values have to 
be evaluated for each laboratory individually. When large cohorts 
of patients have to be analyzed, the samples may be first screened 
for high lysis at a single time point (e.g., t30) and compared with 
NHS (Figure 3A). This efficient approach allows to save both time 
and patient material, but we underline that it should supplement 
and not replace the evaluation of a complete convertase activity 
profile to confirm positivity. In this work, we only used serum 
samples to assess convertase activity, but from our unpublished 
data we know that EDTA plasma samples may be used as well; no 
complement-inhibiting effects of EDTA are observed under the 
described test conditions (Figure S2 in Supplementary Material). 
Furthermore, as an alternative for eculizumab, which is expensive 
and may be difficult to access, the tick protein OmCI [or its com-
mercially available variant Coversin (43)] may be used for C5 
blockage in the first step of the assay (37, 38). Future research 
may benefit from cheaper alternative C5-blocking agents.
The positive samples showed high variation in the degree 
of convertase stabilization: where some sera showed active 
convertases up to t60, other sera showed delayed decay with 
breakdown of convertases between 30 and 60 min (Figure 3B). 
First of all, this may be attributed to the heterogeneity of C3NeF 
autoantibodies, which recognize different neoepitopes of the con-
vertase complex. All C3NeF prevent the natural intrinsic decay 
of the convertase (44), but they vary in the degree of resistance 
they provide against extrinsic decay mediated by complement 
regulators (31, 44–47). Two reports described C3NeF that were 
completely unable to interfere with complement regulators and 
the authors indicated them as likely less pathogenic in vivo, since 
patients with these C3NeF did not present with hypocomple-
mentemia (31, 47). Besides, the interaction of C3NeF with the 
convertase can be dependent on properdin or be independent of 
this positive complement regulator. Properdin-dependent and 
-independent C3NeF types may differ in the degree of convertase 
stabilization they provide (31) and have been related to different 
degrees of terminal pathway activation observed in patients (48, 
49). A recent study identified properdin-dependent C3NeF as 
C5NeF: nephritic factors stabilizing C5 convertases (50). Since in 
our assay whole serum conditions are used in which properdin is 
present, our assay should be able to detect those factors as well. 
Furthermore, few previous reports described autoantibodies 
against the individual components of the convertase, i.e., FB and 
FigUre 4 | Convertase activity profiles of patients with C3 glomerulopathy over disease course. Patient serum samples of P24 (a), P27 (B), P25 (c), and P26 (D) 
from different collection dates associated with different disease states were tested mixed 1:1 with pooled normal human serum (NHS) to a final concentration of 
3.75% in experiments shown in panels (c,D) or 5% in the experiments shown in panels (a,B), since they were performed using different batches of erythrocytes. 
Abbreviations: Acu, acute phase at first clinical presentation of disease; Act, active disease; Part Rem, partial remission; Rem, remission. Heat-inactivated NHS 
(ΔNHS) and an NHS sample from which guinea pig serum were omitted during the second part of the assay (no step 2) served as negative controls for the first and 
second steps, respectively. Representative data are given. Hemolysis levels are given as percentage of full lysis of erythrocytes in water.
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C3b, which may also increase the convertase half-life (19, 51–53). 
However, not much is known of the role of these autoantibodies 
and their occurrence in C3G patients, which tends to be lower than 
the occurrence of C3NeF (19, 52). In addition, our previous work 
indicated that samples of aHUS patients positive for FHaAb may 
also show C3NeF-like stabilizing activity in the assay (37). In this 
cohort, we also checked for presence of FHaAb, but no patients 
were found positive. In conclusion, this variety in factors influenc-
ing convertase activity via different mechanisms may reflect the 
heterogeneity of the stabilized convertase activity profiles in our 
cohort. To distinguish between these factors, additional methods 
using purified components, e.g., enzyme-linked immune sorbent 
assay (ELISA) techniques, are needed.
In total, 16 out of the 27 patients (59%) of the C3G cohort were 
positive in this assay (Figure 3B); 67% positive in DDD patients, 
57% in the C3GN patients, and 50% in the C3G patient group that 
could not be subdivided into DDD or C3GN. Of these 16, 13 were 
children and 3 were adults. Considering that of all convertase-
stabilizing factors described earlier C3NeF is most common in 
C3G, our data are in line with the numbers of C3NeF positive 
patients reported by other studies (15, 19–21, 54).
Commonly used assays for C3NeF are often based on studying 
isolated interactions of C3NeF with convertases assembled out of 
purified proteins on artificial surfaces (ELISA) or on sheep erythro-
cytes (semiquantitative hemolytic assay). In contrast to RbE, these 
do not naturally activate the AP and therefore require complex and 
time-consuming steps to build up the enzyme. Furthermore, in 
some studies, different detection assays were used alongside each 
other. Patients can be variably positive in these different assays, 
again indicating the heterogeneous nature of C3NeF (19, 31).
An important advantage of our method is the direct assess-
ment of convertase stability in whole, unhandled serum, which 
FigUre 5 | Identification of convertase-stabilizing factors in immunoglobulin (Ig) fractions of patients with C3 glomerulopathy. Serum samples of P24 (a), P27 
(B), P25 (c), and P26 (D) were tested mixed 1:1 with pooled normal human serum (NHS) to a final concentration of 5%. Alternatively, the Ig fractions of these 
patients or of pooled normal human plasma (NHP) were added to 5% NHS in an equal volume. Data were collected from three independent experiments; means are 
given with error bars showing SDs. Statistical analysis for test samples compared with NHP Ig from t = 20 to t = 60 as calculated using two-way analysis of variance 
is given for the patient Igs only: **P < 0.01, ***P < 0.001, ns not significant. Heat-inactivated NHS (ΔNHS) and an NHS sample from which guinea pig serum were 
omitted during the second part of the assay (no step 2) served as negative controls for the first and second steps, respectively. Hemolysis levels are given as 
percentage of full lysis of erythrocytes in water.
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allows easy screening for any factor directly or indirectly affecting 
convertase stability, not limited to C3NeF. Moreover, convertases 
are studied in their physiological surroundings where (negative 
and positive) complement regulators and other serum factors 
are present to interact with the convertases. For this reason, we 
believe our method is particularly suited to detect functionally 
relevant C3NeF and other stabilizing factors. The assay is also 
well suited to screen for convertase-influencing factors in other 
pathologies associated with complement dysregulation, such as 
age-related macular degeneration, immune complex-mediated 
membranoproliferative glomerulonephritis, postinfectious glo-
merulonephritis, systemic lupus erythematosus, and acquired 
partial lipodystrophy (30, 55, 56). However, future research may 
focus on further adaptation of the assay with human (renal) 
cells as platforms for convertase assembly, since they best 
reflect physiological circumstances regarding the expression of 
membrane-bound inhibitors and binding places for the soluble 
inhibitor FH.
A limitation of our assay’s serum approach is that it does not 
directly give insight into the nature (autoantibody or genetic 
variant) and mechanism of the convertase-stabilizing factor 
present in the patient’s serum. When clinically relevant, e.g., to 
evaluate whether B cell-depleting therapy may be indicated, this 
nature can be dissected by assessing stabilizing activity in puri-
fied Ig fractions, screening for FHaAb, and genetic analysis, as we 
described in this study.
We have shown that the convertase-stabilizing activity in 
patients P24–P27 resides in the Ig fraction (Figure 5), indicating 
the presence of stabilizing autoantibodies. For these patients, we 
also described the convertase activity during disease progression. 
In three of them (P24, P27, and P25; Figures 4A–C), convertase-
stabilizing factors were present in all samples taken during the 
different stages of disease. By contrast, the stabilizing Igs detected 
in the acute phase of P26 became undetectable in remission 
(Figure 4D). These data are in line with several previous reports 
on C3G/membranoproliferative glomerulonephritis cohorts that 
FigUre 6 | Assessment of convertase activity in a family with complement factor B (FB) mutation and atypical hemolytic uremic syndrome (aHUS). (a) Pedigree 
with carriers of the FB p.Lys323Glu mutation and/or aHUS. No genetic information of this variation was available for I. 2 who is deceased. (B) Analysis of convertase 
stability in available samples from seven family members. The sera were tested mixed 1:1 with normal human serum (NHS) to a final concentration of 5%. Data for 
each test sample were obtained from three independent experiments; means are given with error bars showing SDs. Statistical analysis for test sera compared with 
NHS from t = 20 to t = 60 as calculated using two-way analysis of variance is given: *P < 0.05, ***P < 0.001, ns not significant. (c) Assessment of the presence of 
convertase-stabilizing factors in the immunoglobulin (Ig) fraction of aHUS patient III. 6. Purified Igs from patient plasma or pooled normal human plasma (NHP) were 
added in an equal volume to 5% NHS. Data were collected from three independent experiments; means are given with error bars showing SDs. (B,c) Heat-
inactivated NHS (ΔNHS) and an NHS sample from which guinea pig serum were omitted during the second part of the assay (no step 2) served as negative controls 
for the first and second steps, respectively. Hemolysis levels are given as percentage of full lysis of erythrocytes in water.
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showed a fluctuation in C3NeF activity over disease course in 
at least one-third of all positive patients (15, 20, 34). Whereas 
in some patients C3NeF were persistently present, in others 
they appeared or disappeared during follow-up. Above that, in 
these studies no correlation was found between C3NeF presence, 
plasma C3 levels, and clinical recovery. More longitudinal stud-
ies are needed to further examine the contribution of C3NeF to 
disease progression and to establish its value as a (prognostic) 
disease biomarker.
Even though we did not find patients positive for FHaAb in the 
described cohort, it is important to screen for these autoantibod-
ies, since they may also indirectly increase convertase stability by 
impairing the convertase regulation by FH (37). FHaAb occur 
in around 10% of C3G cases and have different characteristics 
than those occurring in aHUS cases, for example, regarding their 
target epitope on FH and their pathological consequences (57, 
58). Moreover, FHaAb have been previously reported in simul-
taneous presence of C3NeF, but the combined role of these two 
autoantibodies in mediating AP activation remains unclear and 
requires further investigation (58).
Increased stability of convertases cannot only be caused by 
autoantibodies but may also be due to genetic aberrations. We 
confirmed that the stabilizing C3NeF-like activity detected in 
the aHUS patient with known FB mutation (p.Lys323Glu) is 
due to its aberrant FB activity: increased convertase stability in 
serum segregated with the FB mutation in both affected and 
non-affected family members (Figure  6B), while the purified 
Igs from this patient did not support convertase stabilization 
(Figure  6C). This increased convertase half-life associated 
with the FB mutation is in line with previous functional assays 
showing that this particular variation causes resistance of the C3 
convertase to decay by FH and DAF (41). The fact that a carrier 
of the mutation shows increased convertase stability in our assay 
while not being affected with aHUS is supportive for the theory 
of the incomplete penetrance of mutations in complement genes 
in aHUS. This theory postulates that multiple (environmental) 
triggers are required for the actual development of the disease 
(24). Thus, we show that our assay is also capable as a functional 
assay for identifying gain-of-function mutations in the building 
blocks of the AP convertase.
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In conclusion, we present optimization of an efficient, robust, 
and reliable assay for detection and characterization of convertase-
stabilizing factors (C3NeF and some genetic changes) in patients 
with complement-mediated renal diseases and for monitoring 
these patients during treatment. This assay can be used for study-
ing the role of these factors in the pathophysiology of C3G or 
related disorders and may contribute to the development of more 
personalized treatment strategies.
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